Vectura Group PLC (VEC) PT Lowered to GBX 180 at J P Morgan Chase & Co
Vectura Group PLC (LON:VEC) had its target price decreased by equities researchers at J P Morgan Chase & Co from GBX 210 ($2.83) to GBX 180 ($2.43) in a research report issued to clients and investors on Thursday, Marketbeat Ratings reports. The firm currently has an “overweight” rating on the stock. J P Morgan Chase & Co’s price objective would suggest a potential upside of 79.64% from the company’s previous close.
Other analysts have also recently issued reports about the stock. Citigroup Inc. reduced their target price on shares of Vectura Group PLC from GBX 200 ($2.70) to GBX 180 ($2.43) and set a “buy” rating for the company in a report on Monday, September 18th. Shore Capital reaffirmed a “buy” rating on shares of Vectura Group PLC in a report on Wednesday, August 16th. Peel Hunt reaffirmed a “hold” rating and set a GBX 160 ($2.16) target price on shares of Vectura Group PLC in a report on Wednesday, August 16th. N+1 Singer reaffirmed a “hold” rating on shares of Vectura Group PLC in a report on Thursday, June 29th. Finally, Panmure Gordon reaffirmed a “buy” rating on shares of Vectura Group PLC in a report on Wednesday, August 30th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of GBX 199.63 ($2.69).
Vectura Group PLC (VEC) traded up 0.10% on Thursday, reaching GBX 100.20. 806,768 shares of the company traded hands. The stock’s market capitalization is GBX 679.86 million. The stock’s 50-day moving average is GBX 107.83 and its 200-day moving average is GBX 125.26. Vectura Group PLC has a 1-year low of GBX 88.90 and a 1-year high of GBX 166.97.
In other news, insider Bruno Angelici purchased 70,000 shares of the company’s stock in a transaction on Tuesday, September 12th. The stock was acquired at an average cost of GBX 99 ($1.33) per share, for a total transaction of £69,300 ($93,434.00). Also, insider Andrew Derodra purchased 82,000 shares of the company’s stock in a transaction on Thursday, September 7th. The stock was purchased at an average price of GBX 90 ($1.21) per share, with a total value of £73,800 ($99,501.15). Over the last quarter, insiders acquired 152,293 shares of company stock valued at $14,339,837.
About Vectura Group PLC
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.